Redcliffe Labs launches Elecsys AMH Plus test with Roche Diagnostics India for PCOS diagnosis

Redcliffe Labs has launched the Elecsys AMH Plus blood test in collaboration with Roche Diagnostics India to support identification of Polycystic Ovarian Morphology (PCOM) and aid in the diagnosis of Polycystic Ovary Syndrome (PCOS). The launch addresses a gap, as global estimates suggest up to 70 per cent of cases remain undiagnosed.

In India, nearly one in five women of reproductive age are affected. The Elecsys AMH Plus test uses a blood sample to measure Anti-Müllerian Hormone (AMH), a biomarker linked to PCOM and present in nearly four out of five PCOS cases in India.

The test replaces transvaginal ultrasound (TVUS) with a blood-based method. It is designed as a minimally invasive test, suitable for all women, and can be conducted without dependence on menstrual cycles. It provides standardised results and is designed to be reliable across body types, including women with elevated BMI.

The Elecsys AMH Plus test is supported by validation at global and local levels. International guidelines released in 2023 recognise AMH as an alternative to ultrasound for assessing PCOM. In India, the Federation of Obstetric and Gynaecological Societies of India has endorsed its use in aiding PCOS diagnosis. Clinical studies, including APHRODITE and HARMONIA, report that at a cut-off of 3.2 ng/mL, the test delivers 89 per cent sensitivity and 85 per cent specificity.

Aditya Kandoi said, “PCOS is one of the most common yet underdiagnosed conditions affecting women today. With this breakthrough test, we are removing barriers and enabling timely, reliable diagnosis. Our mission is to empower women with proactive health solutions that transform their reproductive and metabolic journeys.”

Dr Rishubh Gupta said, “We are proud to collaborate with Redcliffe Labs in advancing women’s health. By introducing the Elecsys AMH Plus blood test, Redcliffe Labs is making PCOS diagnostics more accessible and less intimidating. This reinforces our commitment to bridging healthcare gaps by consistently bringing Roche’s world-class clinical innovations to the Indian market.”

With this launch, Redcliffe Labs will expand its diagnostics portfolio focused on women’s health across India.